US Stock MarketDetailed Quotes
CLDX Celldex Therapeutics
- 33.200
- +0.340+1.03%
Close Sep 27 16:00 ET
- 33.270
- +0.070+0.21%
Post 18:56 ET
2.20BMarket Cap-12072P/E (TTM)
33.315High31.220Low1.37MVolume32.200Open32.860Pre Close44.64MTurnover2.07%Turnover RatioLossP/E (Static)66.29MShares53.18052wk High2.70P/B2.19BFloat Cap22.11052wk Low--Dividend TTM66.10MShs Float3374.997Historical High--Div YieldTTM6.38%Amplitude1.500Historical Low32.673Avg Price1Lot Size
Celldex Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -7.84%-29.33M | -42.25%-40.64M | -3.43%-107.29M | -49.49%-32.53M | 46.03%-18.99M | -22.26%-27.2M | -16.45%-28.57M | -70.31%-103.73M | -49.85%-21.76M | -114.95%-35.19M |
| Net income from continuing operations | -17.51%-35.84M | -11.74%-32.81M | -25.91%-141.43M | -63.50%-43.31M | -42.85%-38.26M | 15.28%-30.5M | -27.38%-29.36M | -59.30%-112.33M | -31.46%-26.49M | -30.96%-26.78M |
| Operating gains losses | --0 | --8K | ---- | ---- | ---- | ---- | ---- | 108.33%2K | 200.00%1K | -5,700.00%-56K |
| Depreciation and amortization | 5.42%797K | 6.75%775K | 3.87%3.01M | 12.78%759K | 14.31%767K | 2.02%756K | -10.48%726K | -5.61%2.9M | -13.38%673K | -10.77%671K |
| Deferred tax | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Other non cash items | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -388.40%-6.86M | --0 | --0 |
| Change In working capital | 286.99%2.82M | -314.25%-12.5M | 445.36%13.46M | 7,563.08%4.98M | 195.79%13.01M | -109.85%-1.51M | 46.90%-3.02M | -269.83%-3.9M | -96.30%65K | -728.56%-13.58M |
| -Change in receivables | -4.93%1.14M | 95.55%-43K | -1,203.43%-2.28M | -1,403.80%-2.38M | -45.65%-134K | 719.18%1.2M | -1,261.97%-967K | -111.12%-175K | -732.00%-158K | -137.86%-92K |
| -Change in prepaid assets | 121.52%599K | -328.10%-6.21M | 161.64%5.9M | 352.01%4.14M | 226.39%1.82M | -108.15%-2.78M | 138.08%2.72M | -411.60%-9.57M | -521.54%-1.64M | 177.68%557K |
| -Change in payables and accrued expense | 258.58%1.71M | -38.66%-4.78M | 200.48%9.38M | 61.34%3.88M | 163.18%8.48M | -97.17%478K | -25.93%-3.45M | -14.51%3.12M | 26.74%2.4M | -635.22%-13.42M |
| -Change in other current assets | ---- | ---- | ---3K | --0 | --0 | ---- | ---- | --0 | --0 | --0 |
| -Change in other current liabilities | -60.00%-632K | -10.87%-1.47M | -83.05%462K | -23.69%-663K | 555.93%2.85M | -2.07%-395K | -131.01%-1.33M | 161.88%2.73M | 2.55%-536K | -591.34%-624K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -7.84%-29.33M | -42.25%-40.64M | -3.43%-107.29M | -49.49%-32.53M | 46.03%-18.99M | -22.26%-27.2M | -16.45%-28.57M | -70.31%-103.73M | -49.85%-21.76M | -114.95%-35.19M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -4,114.00%-46.72M | -699.61%-315.21M | -217.61%-105.78M | -648.36%-171.16M | -49.51%11.65M | -95.40%1.16M | 406.45%52.57M | 141.61%89.94M | 264.76%31.21M | 110.17%23.07M |
| Net PPE purchase and sale | 33.17%-274K | 41.20%-344K | 0.55%-1.82M | -183.40%-666K | 54.49%-157K | 39.08%-410K | -1.74%-585K | -46.36%-1.83M | 33.62%-235K | -86.49%-345K |
| Net investment purchase and sale | -3,051.02%-46.45M | -692.37%-314.87M | -213.37%-103.96M | -642.15%-170.5M | -49.44%11.8M | -93.94%1.57M | 385.20%53.15M | 142.66%91.7M | 269.15%31.45M | 110.30%23.34M |
| Net other investing changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 155.56%69K | --0 | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -4,114.00%-46.72M | -699.61%-315.21M | -217.61%-105.78M | -648.36%-171.16M | -49.51%11.65M | -95.40%1.16M | 406.45%52.57M | 141.61%89.94M | 264.76%31.21M | 110.17%23.07M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 2,690.98%3.71M | 62,740.35%436.11M | 5,259.62%218.46M | 15,482.37%217.37M | -88.86%257K | 87.32%133K | 128.29%694K | -98.50%4.08M | 227.46%1.4M | -99.15%2.31M |
| Net common stock issuance | --0 | --432.3M | --216.22M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | 2,690.98%3.71M | 449.57%3.81M | -45.14%2.24M | -17.42%1.15M | -88.86%257K | 87.32%133K | 128.29%694K | 64.42%4.08M | 227.46%1.4M | 15.07%2.31M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 2,690.98%3.71M | 62,740.35%436.11M | 5,259.62%218.46M | 15,482.37%217.37M | -88.86%257K | 87.32%133K | 128.29%694K | -98.50%4.08M | 227.46%1.4M | -99.15%2.31M |
| Net cash flow | ||||||||||
| Beginning cash position | 112.62%115.08M | 18.30%34.81M | -24.82%29.43M | 13.73%21.13M | -0.62%28.22M | 113.98%54.12M | -24.82%29.43M | -10.71%39.14M | -74.26%18.58M | -34.63%28.4M |
| Current changes in cash | -179.31%-72.34M | 225.03%80.26M | 155.44%5.39M | 26.13%13.68M | 27.79%-7.09M | -933.30%-25.9M | 278.30%24.69M | -106.99%-9.71M | 132.83%10.85M | -134.16%-9.82M |
| End cash Position | 51.43%42.74M | 112.62%115.08M | 18.30%34.81M | 18.30%34.81M | 13.73%21.13M | -0.62%28.22M | 113.98%54.12M | -24.82%29.43M | -24.82%29.43M | -74.26%18.58M |
| Free cash flow | -7.23%-29.6M | -40.57%-40.98M | -3.36%-109.11M | -50.93%-33.2M | 46.11%-19.15M | -20.46%-27.61M | -16.11%-29.15M | -69.83%-105.56M | -47.86%-22M | -114.63%-35.54M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data